Hypoxia Is the Driving Force Behind GBM and Could Be a New Tool in GBM Treatment.
Hypoxia Is the Driving Force Behind GBM and Could Be a New Tool in GBM Treatment.
复制标题
DOI：
10.1615/critreveukaryotgeneexpr.2015015601
复制
发表时间：
2015
影响因子：
1.6
通讯作者：
R. Kalkan
中科院分区：
文献类型：
--
作者：
R. Kalkan
根据肿瘤的遗传和表观遗传背景，胶质母细胞瘤（GBM）可分为两种不同的疾病实体。肿瘤位置与其遗传异常的高度变异性相关。由于肿瘤细胞的细胞异质性和侵入健康组织的内在能力，这些肿瘤的治疗过程常常不成功。这些肿瘤的致命结果鼓励研究人员寻找与预后和治疗计划相关的新标志物。在本次通讯中，我们讨论了缺氧作为多形性胶质母细胞瘤的新治疗靶点以及缺氧对癌细胞的分子和表型影响。我们重点关注信号通路的抑制，这与缺氧介导的胶质母细胞瘤干细胞的维持和缺氧诱导因子 1-α (HIFlα) 的敲低有关。这一讨论可能有助于开发新的针对性治疗方法。此外，我们强调缺氧诱导因子（HIF）可能成为 GBM 治疗有吸引力的分子靶点。
Glioblastoma (GBM) can be divided into two distinct disease entities according to the genetic and the epigenetic background of the tumor. Tumor location is associated with high variability in its genetic abnormalities. The treatment procedures for these tumors are often unsuccessful because of the cellular heterogeneity and intrinsic ability of the tumor cells to invade healthy tissues. The fatal outcomes of these tumors have encouraged researchers to find new markers associated with prognosis and treatment planning. In the present communication, we discuss hypoxia as a new therapeutic target of glioblastoma multiforme and the molecular and phenotypic effects of hypoxia on cancer cells. We focus on the inhibition of the signaling pathways, which is associated with the hypoxia-mediated maintenance of glioblastoma stem cells and the knockdown of the hypoxia-inducible factor 1-alpha (HIFlα). This discussion may contribute to the development of new specifically targeted treatments. Furthermore, we highlight the idea that hypoxia-inducible factors (HIFs) could be attractive molecular targets for GBM therapeutics.